Bicycle Therapeutics PLC
NASDAQ:BCYC
Bicycle Therapeutics PLC
NASDAQ:BCYC
Price:
4.635
USD
-1.38%
Market Cap:
$321.5m
Relative Value
The Relative Value of one
BCYC
stock under the Base Case scenario is
2.259
USD.
Compared to the current market price of 4.635 USD,
Bicycle Therapeutics PLC
is
Overvalued by 51%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BCYC
Relative Value
Base Case
2.259
USD
Overvaluation 51%
Multiples Across Competitors
BCYC Competitors Multiples
Bicycle Therapeutics PLC Competitors
Bicycle Therapeutics PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
325.7m USD | 11.3 | -1.3 | 1.2 | 1.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
367.1B USD | 6 | 87.9 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.9B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 6 | 20.6 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD | 9.6 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
64.8B AUD | 3 | 32.9 | 11 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.4B EUR | 10.3 | 33.1 | 35.8 | 36.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
